Regulus Therapeutics (RGLS) Earnings Date, Estimates & Call Transcripts $1.54 +0.01 (+0.65%) (As of 01:00 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Regulus Therapeutics Latest Earnings SummaryActual EPS (Nov. 7) -$0.21 Missed By -$0.03 Consensus EPS (Nov. 7) -$0.18 Regulus Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.21, which missed analysts' consensus estimates of -$0.18 by $0.03. With a trailing EPS of -$1.07, Regulus Therapeutics' earnings are expected to decrease next year, from ($0.88) to ($1.38) per share. Get Regulus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regulus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRGLS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RGLS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Regulus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.19-$0.11-$0.15Q2 20242-$0.13-$0.11-$0.12Q3 20242-$0.13-$0.12-$0.13Q4 20242-$0.22-$0.13-$0.18FY 20248-$0.67-$0.47-$0.57Q1 20251-$0.23-$0.23-$0.23Q2 20252-$0.23-$0.20-$0.22Q3 20252-$0.24-$0.21-$0.23Q4 20252-$0.23-$0.20-$0.22FY 20257($0.93)($0.84)($0.89) Regulus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/7/2024Q3 2024-$0.18-$0.21 -$0.03-$0.21--8/8/2024--$0.17-$0.17--$0.17--5/9/2024Q1 2024-$0.15-$0.29 -$0.14-$0.29--3/21/2024Q4 2023-$0.40-$0.40--$0.40--11/9/2023Q3 2023-$0.36-$0.40 -$0.04-$0.40--8/8/2023Q2 2023-$0.39-$0.37+$0.02-$0.37-- Get the Latest News and Ratings for RGLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$0.41-$0.42 -$0.01-$0.42--3/23/2023Q4 2022-$0.49-$0.40+$0.09-$0.40-- Regulus Therapeutics Earnings - Frequently Asked Questions When did Regulus Therapeutics announce their last quarterly earnings? Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on RGLS's earnings history. Did Regulus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Regulus Therapeutics (NASDAQ:RGLS) missed the analysts' consensus estimate of ($0.18) by $0.03 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. RGLS's actual earnings. How much profit does Regulus Therapeutics generate each year? Regulus Therapeutics (NASDAQ:RGLS) has a recorded net income of -$30.04 million. RGLS has generated -$1.07 earnings per share over the last four quarters. What is Regulus Therapeutics's EPS forecast for next year? Regulus Therapeutics's earnings are expected to decrease from ($0.88) per share to ($1.38) per share in the next year. More Earnings Resources from MarketBeat Related Companies XOMA Earnings Date Rigel Pharmaceuticals Earnings Date Vanda Pharmaceuticals Earnings Date Lexicon Pharmaceuticals Earnings Date Verastem Earnings Date Achieve Life Sciences Earnings Date Agenus Earnings Date Fortress Biotech Earnings Date SAB Biotherapeutics Earnings Date Curis Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. This page (NASDAQ:RGLS) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts